Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: Prognostic impact

Histology and Histopathology

Volumn 24, Issue 7, 2009, Pages 869-877

  Hildenbrand, Ralf ^a,b   Schaaf, Antonela ^a   Dorn Beineke, Alexandra ^a   Allgayer, Heike ^a   Sütterlin, Marc ^a   Marx, Alexander ^a   Stroebel, Philipp ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Breast cancer; Prognostic impact; Tumor stroma; UPA system

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; TUMOR MARKER; UROKINASE; UROKINASE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST TUMOR; CASE CONTROL STUDY; CLASSIFICATION; COHORT ANALYSIS; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; KAPLAN MEIER METHOD; LASER; METABOLISM; MICRODISSECTION; MIDDLE AGED; MORTALITY; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS; STROMA CELL; SURVIVAL; TIME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; LASERS; MICRODISSECTION; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGNOSIS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; STROMAL CELLS; SURVIVAL ANALYSIS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 68849088489     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Andreasen P.A., Egelund R. and Petersen H.H. (2000). The plasminogen activator system in tumor growth, invasion, and metastasis. Cell Mol. Life Sci. 57, 25-40
2. Arens N., Bleyl U. and Hildenbrand R. (2005). HER2/neu, p53, Ki67, and hormone receptors do not change during neoadjuvant chemotherapy in breast cancer. Virchows Arch. 446, 489-496.
3. Bianchi E., Cohen R.L., Thor A.T., Todd III R.F., Mizukami I.F., Lawrence D.A., Ljung B.M., Shumann M.A. and Smith H.S. (1994). The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res. 54, 861-866.
4. Binder B.R., Mihaly J. and Prager G.W. (2007). uPAR-uPA-PAI-1 interactions and signaling: A vascular biologist's view Thromb. Haemost. 97, 336-342.
5. Constantini V., Zacharski L.R., Memoli V.A., Kudryk B.J., Rousseau S.M. and Stump D.C. (1991). Occurrence of components of fibrinolysis pathways in situ in neoplastic and non-neoplastic human breast tissue. Cancer Res. 51, 354-358.
6. Christensen L., Simonsen A.C.W., Heegaard C.W., Moestrup S.K., Andersen J.A. and Andreasen P.A. (1996). Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen activator inhibitor, urokinase receptor and ·2-macroglobulin receptor in human breast carcinomas. Int. J. Cancer 66, 441-452.
7. Del Vecchio S., Stoppelli M.P., Carriero M.V., Fonti R., Massa O., Li P.Y., Botti G., Cerra M., D'Aiuto G., Esposito G. and Salvatore M. (1993). Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: comparison with urokinase levels. Cancer Res. 53, 3198-3206.
8. Dublin E., Hanby A., Patel N.K., Liebmann R. and Barnes D. (2000). Immunohistochemical expression of uPA, uPAR and PAI-1 in breast carcinoma. AJP 157, 1219-1227.
9. Durand M.K.V., Bodker J.S., Christensen A., Dupont D.M., Hansen M., Jensen J.K., Kjelgard S., Mathiasen L., Pedersen E.K., Skeldal S., Wind T and Andreasen P.A. (2004) Plasminogen activatot inhibitor-1 and tumour growth, invasion, and metastasis. Thromb. Haemost. 91, 438-449.
10. Dvorak H.F. (1986). Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 315, 1650-1659.
11. Elston C.W. and Ellis I.O. (1991) Pathological prognostic factor in breast cancer. 1. The value of histological grade in breast cancer: experience from a large study with long term follw-up. Histopathology 19, 403-410.
12. Foekens J.A., Peters H.A., Look M.P., Portengen H., Schmitt M., Kramer M.D., Brünner N., Jänicke F., Meijer-van Gelder M.E., Henzen-Logmans S.C., van Putten W.L.J. and Klijn J.G.M. (2000) The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res. 60, 636-643.
13. Haas S., Park T.W., Hahne J.C. and Fischer H.P. (2008). Influence of preoperative core biopsies on uPA/PAI-1 expression in breast cancer tissue. Virchows Arch, 452, 277-283.
14. Harbeck N., Kates R.E., Gauger K., Willems A., Kiechle M., Magdolen V. and Schmitt M. (2004). Urokinase-type plasminogen (uPA) and its inhibitor PAI-1: novel tumor-derived factors with high prognostic and predictive impact in breast cancer. Thomb. Haemost. 91,450-456.
15. Harbeck N., Kates R.E., Look M.P., Meijer-van Gelder M.E., Klijn J.G.M., Krüger A., Kiechle M., Jänicke F., Schmitt M. and Foekens J.A. (2002). Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type-1. Cancer Res. 62, 4617-4622.
16. Harbeck N., Thomssen C., Berger U., Ulm K., Kates R.E., Höfler H., Jänicke F., Graeff H. and Schmitt M. (1999). Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse. Breast Cancer Res. Treat. 54, 147-157.
17. Hildenbrand R., Jansen C., Wolf G., Böhme B., Berger S., von Minckwitz G., Hörlin A., Kaufmann M. and Stutte H.J. (1998). Transforming growth factor-ß stimulates urokinase expression in tumor-associated macrophages of the breast. Lab. Invest. 78, 59-71.
18. Hildenbrand R., Wolf G., Böhme B., Bleyl U. and Steinborn A. (1999). Urokinase plasminogen activator receptor (CD87) expression of tumor-associated macrophages in ductal carcinoma in situ, breast cancer, and resident macrophages of normal breast tissue. J Leukocyte Biol. 66, 40-49.
19. Hildenbrand R., Gandhari M., Stroebel P., Marx A., Allgayer H. and Arens N. (2008). The urokinase-system- role of cell proliferation and apoptosis. Histol. Histopathol. 23, 227-236.
20. Jaenicke F., Schmitt M., Hafter R., Hollrieder A., Babic R., Ulm K., Gossmer W. and Graeff H. (1990). Urokinase-type plasminogen activator (uPA antigen is a predictor of early relapse in breast cancer. Fibrinolysis 4, 69-78.
21. Jahkola T., Toivonen T., von Smitten K., Virtanen I., Wasenius V.M. and Blomqvist C. (1999). Cathepsin D, urokinase plasminogen activator and typ-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin -C and other factors. Br. J. Cancer 80, 167-174.
22. Kaplan E.L. and Meier P. (1958). Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc, 53, 457-481.
23. McMahon G.A., Petitclerc E., Stefansson S., Smith E., Wong M.K., Westrick R.J., Ginsburg D., Brooks P.C. and Lawrence D.A. (2001). Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J. Biol. Chem. 276, 33964-33968.
24. Remmele W. and Stegner H.E. (1987). Vorschlag zur einheitlichen Definierung eines immureaktiven Score (IRS) für den immunhistochemischen Östrogenrezeptornachweis (ER-ICA im Mammakarzinomgewebe. Pathologe 8, 138-140.
25. Schmalfeldt B., Kuhn W., Reuning U., Pache L., Dettmar P., Schmitt M., Jänicke F., Höfler H. and Graeff H. (1995). Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, ist receptor, and inhibitors types -1 and -2. Cancer Res. 55, 3958-396.
26. Schmitt M., Harbeck N., Thomssen C., Wilhelm O., Magdolen V., Reuning U., Ulm K., Höfler H., Jänicke F. and Graeff H. (1997). Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb. Heamost. 78, 285-296.
27. Zuk J.A. and Walker R.A. (1987). Immunohistochemical analysis of HLA antigens and mononuclear infiltrates of benign and malignant breast. J. Pathol. 152, 275-285.